Stay up to date on the latest information you need to devise benefit designs, make coverage decisions, and further value-based healthcare! Sign up for our newsletter or print publications today by entering your contact information below and clicking "Subscribe".
The 3-drug regimen should be considered a new standard of care. The 61% improvement in PFS is “unprecedented in randomized studies that compare novel treatments for relapsed or refractory multiple myeloma,” reported Antonio Palumbo, MD.
The first-in-class antibody-drug conjugate rovalpituzumab tesirine (Rova-T) may be a new treatment option for patients with small-cell lung cancer (SCLC), which has a very poor prognosis and few treatment options.